What do systematic reviews say?

Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy

The review found no eligible studies for this question.

• Marine‐derived n‐3 fatty acids therapy for stroke 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy

Marine‐derived n‐3 fatty acids therapy showed no clear difference in recurrent events (both ischaemic and haemorrhagic stroke) compared with no marine‐derived n‐3 fatty acids therapy (low certainty).

• Marine‐derived n‐3 fatty acids therapy for stroke 2022 · Cochrane Headline outcomes only
  RR 0.69 [0.31, 1.55]
  3 studies · 1819 participants
  Low

Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy

• Marine‐derived n‐3 fatty acids therapy for stroke 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 58 participants
  Very low

Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy

It is very uncertain whether marine‐derived n‐3 fatty acids therapy changes recurrent events: fatal or non‐fatal (same type of stroke, i.e.… compared with no marine‐derived n‐3 fatty acids therapy (very low certainty).

• Marine‐derived n‐3 fatty acids therapy for stroke 2022 · Cochrane Headline outcomes only
  RR 0.41 [0.02, 8.84]
  1 study · 18 participants
  Very low